Table 1 Clinicopathological characteristics of patients and expression of SRPK1 in colon cancer samples
From: SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer
Clinicopathological | No. (%) |
|---|---|
Sex | |
Male | 83 (56.1) |
Female | 65 (43.9) |
Age (years) | |
≤ 60 | 47 (31.8) |
> 60 | 101 (68.2) |
Stage (AJCC) | |
I | 40 (27.0) |
II | 20 (13.5) |
III | 54 (36.5) |
IV | 34 (23.0) |
T classification | |
T1 | 25 (16.9) |
T2 | 22 (14.9) |
T3 | 24 (16.2) |
T4 | 77 (52.0) |
N classification | |
N0 | 72 (48.6) |
N1 | 53 (35.8) |
N2 | 18 (12.2) |
N3 | 5 (3.4) |
M classification | |
M0 | 114 (77.0) |
M1 | 34 (23.0) |
Survival (n = 75) | |
Alive | 51 (68.0) |
Dead | 24 (32.0) |
Survival time of patients with low SRPK1 expression | |
Mean | 45.03 |
Median | 47.00 |
Survival time of patients with high SRPK1 expression | |
Mean | 38.82 |
Median | 46.00 |
Expression of SRPK1 | |
Low expression | 51(34.5) |
High expression | 97(65.5) |